Novavax has transitioned into a royalty-driven model, with Q4 profitability and 73% of revenue from licensing and royalties.

A rise in tuberculosis cases in Malaysia triggered social media posts falsely claiming that the bacteria responsible for the disease were deliberately inserted into Pfizer's Comirnaty Covid-19 vaccine ...

Pfizer stock rises after FDA fully approves Braftovi combo for metastatic colorectal cancer with BRAF V600E mutation.

After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.